Navco Pharmaceuticals Inc.
NAV.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -90.17% | -86.14% | -60.56% | -38.35% | 98.77% |
| Depreciation & Amortization | -97.57% | -38.91% | 43.96% | 67.49% | 97.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -90.55% | -84.70% | -57.74% | -35.17% | 98.63% |
| Operating Income | 90.55% | 84.70% | 57.74% | 35.17% | -99.98% |
| Income Before Tax | -280.45% | 60.12% | 37.75% | 20.63% | 113.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -280.45% | 60.12% | 37.75% | 20.63% | 113.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -280.45% | 60.12% | 37.75% | 20.63% | 113.84% |
| EBIT | 90.55% | 84.70% | 57.74% | 35.17% | -99.98% |
| EBITDA | 94.04% | 88.38% | 62.40% | 39.39% | -99.73% |
| EPS Basic | -198.32% | 70.74% | 56.56% | 43.29% | 117.12% |
| Normalized Basic EPS | 91.76% | 87.27% | 69.50% | 52.11% | -49.12% |
| EPS Diluted | -198.32% | 70.74% | 56.56% | 43.29% | 117.12% |
| Normalized Diluted EPS | 91.76% | 87.27% | 69.50% | 52.11% | -49.12% |
| Average Basic Shares Outstanding | 20.26% | 29.69% | 64.75% | 77.28% | 60.82% |
| Average Diluted Shares Outstanding | 20.26% | 29.69% | 64.75% | 77.28% | 60.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |